CL2014002416A1 - Anticuerpos humanos anti-cd27, métodos y usos - Google Patents

Anticuerpos humanos anti-cd27, métodos y usos

Info

Publication number
CL2014002416A1
CL2014002416A1 CL2014002416A CL2014002416A CL2014002416A1 CL 2014002416 A1 CL2014002416 A1 CL 2014002416A1 CL 2014002416 A CL2014002416 A CL 2014002416A CL 2014002416 A CL2014002416 A CL 2014002416A CL 2014002416 A1 CL2014002416 A1 CL 2014002416A1
Authority
CL
Chile
Prior art keywords
antibodies
methods
human anti
human
Prior art date
Application number
CL2014002416A
Other languages
English (en)
Inventor
Juan Carlos Almagro
John Wheeler
John Chen
Johan Fransson
Natalie Fursov
Damon Hamel
Thomas Malia
Galina Obmolova
Tatiana Ort
Michael Rycyzyn
Michael Scully
Raymond Sweet
Alexey Teplyakov
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CL2014002416A1 publication Critical patent/CL2014002416A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CL2014002416A 2012-03-15 2014-09-12 Anticuerpos humanos anti-cd27, métodos y usos CL2014002416A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261611332P 2012-03-15 2012-03-15

Publications (1)

Publication Number Publication Date
CL2014002416A1 true CL2014002416A1 (es) 2015-01-16

Family

ID=49157853

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014002416A CL2014002416A1 (es) 2012-03-15 2014-09-12 Anticuerpos humanos anti-cd27, métodos y usos

Country Status (28)

Country Link
US (6) US9102737B2 (es)
EP (1) EP2825200A4 (es)
JP (1) JP6487839B2 (es)
KR (1) KR102153374B1 (es)
CN (1) CN104284678B (es)
AR (1) AR090356A1 (es)
AU (1) AU2013232087B2 (es)
BR (2) BR122020002414B1 (es)
CA (1) CA2867299C (es)
CL (1) CL2014002416A1 (es)
CO (1) CO7071095A2 (es)
CR (1) CR20140415A (es)
EA (1) EA030828B1 (es)
EC (1) ECSP14018641A (es)
GT (1) GT201400193A (es)
HK (1) HK1206251A1 (es)
JO (1) JO3787B1 (es)
MX (1) MX363946B (es)
MY (1) MY175224A (es)
NZ (1) NZ629697A (es)
PE (1) PE20142242A1 (es)
PH (2) PH12014502011B1 (es)
SG (2) SG11201405437QA (es)
TW (2) TWI576354B (es)
UA (1) UA121844C2 (es)
UY (1) UY34680A (es)
WO (1) WO2013138586A1 (es)
ZA (2) ZA201407440B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ602892A (en) 2010-04-13 2014-08-29 Celldex Therapeutics Inc Antibodies that bind human cd27 and uses thereof
PL2686347T3 (pl) 2011-03-16 2018-10-31 Argenx Bvba Przeciwciała przeciwko CD70
WO2014140374A2 (en) * 2013-03-15 2014-09-18 Novo Nordisk A/S Monovalent cd27 antibodies
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
FR3025517B1 (fr) * 2014-09-10 2016-12-23 Repropharm Ligands potentialisants de la bioactivite des gonadotrophines
WO2017044752A1 (en) * 2015-09-10 2017-03-16 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Anti-fibrotic effect of cd70
BR112018006360A2 (pt) 2015-09-30 2018-10-09 Janssen Biotech Inc anticorpos agonísticos que se ligam especificamente ao cd40 humano e métodos de uso
US11466253B2 (en) 2015-10-22 2022-10-11 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
EP3364995B1 (en) * 2015-10-23 2021-08-04 Apogenix AG Single-chain cd27-receptor agonist proteins
US20170233480A1 (en) 2015-12-31 2017-08-17 Development Center For Biotechnology Anti-vegfr antibody and uses thereof
JP7038064B2 (ja) 2016-04-18 2022-03-17 セルデックス セラピューティクス インコーポレイテッド ヒトｃｄ４０に結合するアゴニスト抗体およびその使用
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
JOP20190055A1 (ar) * 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
EP3524624A4 (en) * 2016-09-29 2020-06-17 Jiangsu Hengrui Medicine Co., Ltd. ANTI-CD27 ANTIBODIES, ANTI-BINDING FRAGMENT THEREOF AND MEDICAL USES THEREOF
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
AU2017382234B2 (en) * 2016-12-23 2025-01-30 Macrogenics, Inc. ADAM9-binding molecules, and methods of use thereof
BR112019023608A2 (pt) 2017-05-12 2020-05-26 Crispr Therapeutics Ag Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
WO2019009879A1 (en) * 2017-07-03 2019-01-10 Development Center For Biotechnology ANTI-VEGFR ANTIBODIES AND USES THEREOF
WO2019037131A1 (zh) * 2017-08-25 2019-02-28 深圳市博奥康生物科技有限公司 一种cd27真核表达载体的构建及其高表达细胞株的制备
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
WO2019156223A1 (ja) * 2018-02-09 2019-08-15 国立大学法人大阪大学 チクングニアウイルスに対する抗体またはその抗原結合断片、およびその用途
CN111511767A (zh) * 2018-03-28 2020-08-07 江苏恒瑞医药股份有限公司 抗cd27抗体、其抗原结合片段及其医药用途
JP7680208B2 (ja) * 2018-04-04 2025-05-20 ブリストル－マイヤーズ スクイブ カンパニー 抗ｃｄ２７抗体およびその使用
EP3774898A4 (en) * 2018-04-13 2022-01-26 Dingfu Biotarget Co., Ltd. ANTI-CD27 ANTIBODIES AND USE THEREOF
WO2019204462A2 (en) 2018-04-17 2019-10-24 Celldex Therapeutics, Inc. Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
EP3790629A1 (en) 2018-05-11 2021-03-17 CRISPR Therapeutics AG Methods and compositions for treating cancer
MA52889A (fr) 2018-06-15 2021-04-21 Flagship Pioneering Innovations V Inc Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
WO2020123444A1 (en) 2018-12-11 2020-06-18 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療
US20220144961A1 (en) * 2019-03-11 2022-05-12 Xyence Therapeutics, Inc. Cd27-binding antibodies and uses thereof
AU2020267057A1 (en) 2019-04-30 2021-11-18 Crispr Therapeutics Ag Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
JP2022532837A (ja) * 2019-05-24 2022-07-20 エリクシロン・イミュノセラピューティクス・（ホンコン）・リミテッド 抗ｃｓｆ１ｒ抗体、ｉｌ１０融合タンパク質、及びそれらの使用
AU2020339086B2 (en) * 2019-08-30 2024-08-22 Janssen Biotech, Inc. B-cell maturation complex CAR T construct and primers
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
TW202208427A (zh) * 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 人源化抗ｃ５ａ抗體
EP4172323A1 (en) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
CN112646029B (zh) * 2020-12-30 2022-07-29 深圳清华大学研究院 成熟脑源性神经营养因子的抗体及其应用和诊断试剂盒
US20220325287A1 (en) 2021-03-31 2022-10-13 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
CN116120451A (zh) * 2021-06-17 2023-05-16 南京蓝盾生物科技有限公司 抗cd70内化的抗体、抗体偶联物及其应用
KR20240026507A (ko) 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
AU2023236289A1 (en) 2022-03-15 2024-08-15 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
CN115165829B (zh) * 2022-06-29 2025-07-29 上海交通大学 一种定量分析系统性红斑狼疮免疫细胞与功能蛋白的方法及其应用
WO2024054992A1 (en) 2022-09-09 2024-03-14 Bristol-Myers Squibb Company Methods of separating chelator
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
CN118667002A (zh) * 2023-03-16 2024-09-20 上海赛金生物医药有限公司 抗cd27单克隆抗体及其应用
US12180274B2 (en) 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
CN119661718B (zh) * 2025-02-20 2025-06-06 杭州华大生命科学研究院 一种抗cd27纳米抗体及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218525B1 (en) 1988-02-25 2001-04-17 The General Hospital Corporation Nucleic acid encoding CD28
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2134212T3 (es) 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5573924A (en) 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
EP1263788A2 (en) 2000-02-11 2002-12-11 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
US6982361B1 (en) 2000-02-25 2006-01-03 The Regents Of The University Of California Method of screening a compound for anxiolytic activity in an Apolipoprotein e knockout animal
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
JP2005512962A (ja) 2001-09-20 2005-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｐｄｇｆ抗体および設計抗体の産生方法
WO2003068268A2 (en) 2002-02-14 2003-08-21 Bioinvent International Ab Treatment, diagnosis and imaging of disease
CA2516128A1 (en) 2003-02-14 2004-09-02 Sagres Discovery, Inc. Therapeutic targets in cancer
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
KR20080031001A (ko) 2005-06-02 2008-04-07 아스트라제네카 아베 Ｃｄ20에 대한 항체 및 그의 용도
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
JP2011507519A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
EP2090320A1 (en) 2008-02-15 2009-08-19 Helmholtz-Zentrum für Infektionsforschung GmbH Ligands of the Natural Killer (NK) cell surface marker CD27 and therapeutic uses thereof
CA2729567C (en) * 2008-06-30 2018-04-24 Kyowa Hakko Kirin Co., Ltd. Anti-cd27 antibody
WO2010080463A1 (en) * 2008-12-18 2010-07-15 Imclone Llc Antibody humanization
ES2705015T3 (es) * 2009-12-29 2019-03-21 Kyowa Hakko Kirin Co Ltd Anticuerpo anti-CD27
NZ602892A (en) * 2010-04-13 2014-08-29 Celldex Therapeutics Inc Antibodies that bind human cd27 and uses thereof
JP6023706B2 (ja) * 2010-07-09 2016-11-09 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． Ｃｄ２７に対するアゴニスト抗体

Also Published As

Publication number Publication date
BR112014022812A2 (pt) 2017-07-18
ZA201407440B (en) 2016-07-27
PE20142242A1 (es) 2015-01-08
NZ629697A (en) 2017-01-27
US20240141055A1 (en) 2024-05-02
JP2015511965A (ja) 2015-04-23
CR20140415A (es) 2014-11-18
ECSP14018641A (es) 2018-10-31
PH12017501908A1 (en) 2018-10-01
JO3787B1 (ar) 2021-01-31
AR090356A1 (es) 2014-11-05
US9102737B2 (en) 2015-08-11
PH12017501908B1 (en) 2018-10-01
CA2867299C (en) 2019-08-27
ZA201500887B (en) 2016-01-27
HK1206251A1 (en) 2016-01-08
SG11201405437QA (en) 2014-10-30
UY34680A (es) 2013-09-30
WO2013138586A1 (en) 2013-09-19
US10689453B2 (en) 2020-06-23
AU2013232087B2 (en) 2018-02-08
KR20140133940A (ko) 2014-11-20
US10301392B2 (en) 2019-05-28
SG10201710574UA (en) 2018-02-27
KR102153374B1 (ko) 2020-09-10
CN104284678B (zh) 2018-04-24
AU2013232087A1 (en) 2014-09-25
MX2014011100A (es) 2014-12-05
CN104284678A (zh) 2015-01-14
BR122020002414B1 (pt) 2022-03-03
US20200277393A1 (en) 2020-09-03
US20190248910A1 (en) 2019-08-15
EP2825200A1 (en) 2015-01-21
PH12014502011B1 (en) 2018-08-08
CA2867299A1 (en) 2013-09-19
PH12014502011A1 (en) 2014-11-24
JP6487839B2 (ja) 2019-03-20
EA030828B1 (ru) 2018-10-31
TW201345922A (zh) 2013-11-16
US20150299330A1 (en) 2015-10-22
UA121844C2 (uk) 2020-08-10
EP2825200A4 (en) 2015-08-26
EA201491700A1 (ru) 2015-02-27
US11732050B2 (en) 2023-08-22
MY175224A (en) 2020-06-16
MX363946B (es) 2019-04-09
TW201730214A (zh) 2017-09-01
US20130243795A1 (en) 2013-09-19
US9683046B2 (en) 2017-06-20
TWI576354B (zh) 2017-04-01
US20170320957A1 (en) 2017-11-09
CO7071095A2 (es) 2014-09-30
GT201400193A (es) 2017-06-14

Similar Documents

Publication Publication Date Title
CO7071095A2 (es) Anticuerpos humanos anti-cd27, métodos, y usos
IL269045A (en) Aptamers and uses thereof
BR112015001459A2 (pt) anticorpos anti-kit e usos dos mesmos.
EP2803342A4 (en) COLLECTOR FOR HUMAN FACIALS
CL2016000251A1 (es) Anticuerpos anti-activina y usos de los mismos
CL2015001924A1 (es) Anticuerpos anti-pdgfr-beta y usos relacionados.
CO6821892A2 (es) Anticuerpos anti-angptl3 y usos de los mismos
SMT202000512T1 (it) Anticorpi anti-tau umani
IL236916A0 (en) Implant encapsulation and devices and methods using same
CL2015001321A1 (es) Anticuerpos anti-ceacam5 y usos de éstos
BR112015002790A2 (pt) anticorpos asgpr e usos dos mesmos.
CO6940383A2 (es) Anticuerpos anti-erbb3 y usos de los mismos
BR112015006198A2 (pt) conjunto de cadeira
ZA201407927B (en) Anti-egfr antibodies and uses thereof
BR112013007499A2 (pt) piridazinonas - métodos de criação e usos
BR112015004817A2 (pt) bioconjugados compreendendo antígenos modificados e seus usos
EP4379102C0 (en) PATIENT INTERFACE
LT2920197T (lt) Prolinu užblokuoti susegti peptidai, ir jų naudojimas
CO6980627A2 (es) Anticuerpos anti-pfh-tau y sus usos
EP2930714A4 (en) Singing voice synthesizing system and singing voice synthesizing method
EP2830692A4 (en) Patient interface
CO6940376A2 (es) Anticuerpos anti-psgl-1 y usos de los mismos
IL238227A0 (en) Anti-c16orf54 antibodies and methods of use thereof
CL2015001266A1 (es) Anticuerpos de antihemaglutinina y métodos de uso.
DK3453723T3 (da) Anti-ASIC1-antistoffer og anvendelser deraf